Esperion Therapeutics (ESPR) EPS (Weighted Average and Diluted) (2018 - 2026)
Esperion Therapeutics (ESPR) reported EPS (Weighted Average and Diluted) of -$0.1 for Q1 2026, up 52.38% on a YoY basis from -$0.07 in Q1 2025, and down 131.25% quarter-over-quarter from $0.32 in Q4 2025.
Esperion Therapeutics (ESPR) EPS (Weighted Average and Diluted) (2018 - 2026) Analysis & Trends
Esperion Therapeutics has reported EPS (Weighted Average and Diluted) for 9 years, with the latest figure at -$0.1 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 52.38% year-over-year to -$0.1; the trailing twelve-month figure through Mar 2026 stood at -$0.04 (up 95.43% YoY), and the FY2025 full-year result was -$0.11, up 60.71% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.1, down from $0.32 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $0.34 in Q1 2024, with the low at -$1.05 in Q2 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.36 across 5 years, with a median of -$0.33 in 2024.
- The largest YoY upside for EPS (Weighted Average and Diluted) was 390.91% in 2025 against a maximum downside of 161.76% in 2025.
- Esperion Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.74 in 2022, then jumped by 32.43% to -$0.5 in 2023, then soared by 78.0% to -$0.11 in 2024, then soared by 390.91% to $0.32 in 2025, then plunged by 131.25% to -$0.1 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.1 (Q1 2026), $0.32 (Q4 2025), and -$0.16 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 0.31 |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 1.42 |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 5.82 |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 0.02 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.91 |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 0.11 |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -0.40 |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -0.40 |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.80 |
| 10 | Esperion Therapeutics | 49.69 Mn | -118.16 Mn | 45.53 Mn | -0.10 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.10 |
| Dec 31, 2025 | 0.32 |
| Sep 30, 2025 | -0.16 |
| Jun 30, 2025 | -0.06 |
| Mar 31, 2025 | -0.21 |
| Dec 31, 2024 | -0.11 |
| Sep 30, 2024 | -0.15 |
| Jun 30, 2024 | -0.33 |
| Mar 31, 2024 | 0.34 |
| Dec 31, 2023 | -0.50 |
| Sep 30, 2023 | -0.37 |
| Jun 30, 2023 | -0.46 |
| Mar 31, 2023 | -0.79 |
| Dec 31, 2022 | -0.74 |
| Sep 30, 2022 | -0.81 |
| Jun 30, 2022 | -1.05 |
| Mar 31, 2022 | -0.93 |
| Dec 31, 2021 | -1.53 |
| Sep 30, 2021 | -2.62 |
| Jun 30, 2021 | -1.67 |